Diamyd Medical AB (OSTO:DMYD B) FCF Margin % : -149,634.62% (As of Feb. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Diamyd Medical AB FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Diamyd Medical AB's Free Cash Flow for the three months ended in Feb. 2024 was kr-38.91 Mil. Diamyd Medical AB's Revenue for the three months ended in Feb. 2024 was kr0.03 Mil. Therefore, Diamyd Medical AB's FCF Margin % for the quarter that ended in Feb. 2024 was -149,634.62%.

As of today, Diamyd Medical AB's current FCF Yield % is -12.33%.

The historical rank and industry rank for Diamyd Medical AB's FCF Margin % or its related term are showing as below:

OSTO:DMYD B' s FCF Margin % Range Over the Past 10 Years
Min: -47567.38 Med: -3722.11 Max: 4369.79
Current: -47567.38

During the past 13 years, the highest FCF Margin % of Diamyd Medical AB was 4369.79%. The lowest was -47567.38%. And the median was -3722.11%.

OSTO:DMYD B's FCF Margin % is ranked worse than
96.75% of 1046 companies
in the Biotechnology industry
Industry Median: -141.025 vs OSTO:DMYD B: -47567.38

Diamyd Medical AB FCF Margin % Historical Data

The historical data trend for Diamyd Medical AB's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB FCF Margin % Chart

Diamyd Medical AB Annual Data

Trend

Aug14

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

FCF Margin %

Get a 7-Day Free Trial

-2,499.04

4,369.79

-44,937.94

-28,165.42

-22,418.32

Diamyd Medical AB Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
FCF Margin %	Get a 7-Day Free Trial															-25,864.60	-18,352.70	-49,889.19	-91,632.35	-149,634.62

Competitive Comparison of Diamyd Medical AB's FCF Margin %

For the Biotechnology subindustry, Diamyd Medical AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Diamyd Medical AB's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Diamyd Medical AB's FCF Margin % falls into.

Diamyd Medical AB FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Diamyd Medical AB's FCF Margin for the fiscal year that ended in Aug. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Aug. 2023 )	/	Revenue (A: Aug. 2023 )
	=	-122.404	/	0.546
	=	-22,418.32 %

Diamyd Medical AB's FCF Margin for the quarter that ended in Feb. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Feb. 2024 )	/	Revenue (Q: Feb. 2024 )
	=	-38.905	/	0.026
	=	-149,634.62 %

Diamyd Medical AB FCF Margin % Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Diamyd Medical AB (OSTO:DMYD B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (OSTO:DMYD B) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

DMN:Germany

Address

Kungsgatan 29, Stockholm, SWE, SE-111 56

Website

https://www.diamyd.com

Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB (OSTO:DMYD B) Headlines

No Headlines